Effects of fenoldopam infusion in complex cardiac surgical operations: a prospective, randomized, double-blind, placebo-controlled study.

摘要: Aim Fenoldopam mesylate is a short-acting dopamine-1 agonist that has been suggested to be possible reno-protective agent in patients undergoing cardiac surgery. The present study prospective, randomized, double-blind placebo controlled trial conducted determine the effects of fenoldopam population complex operations. Methods Eighty subjects operations with cardiopulmonary bypass (CPB) were enrolled study. Patients randomly assigned either (0.1 microg . kg-1. min-1) or group. infusion started at onset CPB and was maintained for first twelve postoperative hours. parameters renal outcome data collected. Results group had higher oxygen delivery during significantly lower perfusion pressure, although this parameter still within normal range. Blood lactate concentrations similar two groups. Urine output after did not differ between groups, nor function parameters. There rate acute kidney injury (AKI) (10% vs 0%). In subgroup requiring inotropic support more than 48 hours, better, peak arterial blood lower, major morbidity (36% 100%) who received fenoldopam. Conclusion improves quality CPB. receiving catecholamines treat low state, prevents AKI morbidity.